Literature DB >> 32003930

Fixed-dose combinations of lipid-lowering and antihypertensive agents: The way forward?

Areti Sofogianni1, Konstantinos Tziomalos1.   

Abstract

Entities:  

Keywords:  adherence; antihypertensive therapy; combination therapy; statins

Mesh：

Substances：

Year:  2020        PMID： 32003930      PMCID： PMC8030076          DOI： 10.1111/jch.13765

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN： 1524-6175            Impact factor:   3.738


× No keyword cloud information.
  25 in total

1.  Efficacy and Safety of Fixed-dose Combination Therapy With Telmisartan and Rosuvastatin in Korean Patients With Hypertension and Dyslipidemia: TELSTA-YU (TELmisartan-rosuvaSTAtin from YUhan), a Multicenter, Randomized, 4-arm, Double-blind, Placebo-controlled, Phase III Study.

Authors:  Gyu Chul Oh; Jung-Kyu Han; Ki Hoon Han; Min-Su Hyon; Joon Hyung Doh; Moo Hyun Kim; Jin-Ok Jeong; Jang-Ho Bae; Sang Hyun Kim; Byung-Su Yoo; Sang Hong Baek; Moo-Yong Rhee; Sang-Hyun Ihm; Jung Hoon Sung; Young Jin Choi; Soo-Joong Kim; Kyung-Soon Hong; Byoung Kwon Lee; JangHyun Cho; Eun Seok Shin; Jay Young Rhew; Hyunsu Kim; Hyo-Soo Kim
Journal:  Clin Ther       Date:  2018-04-17       Impact factor: 3.393

2.  Global Disparities of Hypertension Prevalence and Control: A Systematic Analysis of Population-Based Studies From 90 Countries.

Authors:  Katherine T Mills; Joshua D Bundy; Tanika N Kelly; Jennifer E Reed; Patricia M Kearney; Kristi Reynolds; Jing Chen; Jiang He
Journal:  Circulation       Date:  2016-08-09       Impact factor: 29.690

3.  Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies.

Authors:  Sarah Lewington; Robert Clarke; Nawab Qizilbash; Richard Peto; Rory Collins
Journal:  Lancet       Date:  2002-12-14       Impact factor: 79.321

Review 4.  Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths.

Authors:  Sarah Lewington; Gary Whitlock; Robert Clarke; Paul Sherliker; Jonathan Emberson; Jim Halsey; Nawab Qizilbash; Richard Peto; Rory Collins
Journal:  Lancet       Date:  2007-12-01       Impact factor: 79.321

5.  Trends in the prevalence, awareness, treatment and control of high low density lipoprotein-cholesterol among United States adults from 1999-2000 through 2009-2010.

Authors:  Paul Muntner; Emily B Levitan; Todd M Brown; Pradeep Sharma; Hong Zhao; Vera Bittner; Stephen Glasser; Meredith Kilgore; Huifeng Yun; J Michael Woolley; Michael E Farkouh; Robert S Rosenson
Journal:  Am J Cardiol       Date:  2013-05-29       Impact factor: 2.778

Review 6.  Meta-analysis of comparative efficacy of increasing dose of Atorvastatin versus Rosuvastatin versus Simvastatin on lowering levels of atherogenic lipids (from VOYAGER).

Authors:  Stephen J Nicholls; Gunnar Brandrup-Wognsen; Mike Palmer; Philip J Barter
Journal:  Am J Cardiol       Date:  2010-01-01       Impact factor: 2.778

7.  Single-pill therapy in the treatment of concomitant hypertension and dyslipidemia (the amlodipine/atorvastatin gemini study).

Authors:  Roy Blank; James LaSalle; Russell Reeves; Jaman Maroni; Lisa Tarasenko; Franklin Sun
Journal:  J Clin Hypertens (Greenwich)       Date:  2005-05       Impact factor: 3.738

8.  Increasing trend of diabetes combined with hypertension or hypercholesterolemia: NHANES data analysis 1999-2012.

Authors:  Yongfeng Song; Xiaoyun Liu; Xiaolin Zhu; Bin Zhao; Bo Hu; Xia Sheng; Lan Chen; Miao Yu; Tao Yang; Jiajun Zhao
Journal:  Sci Rep       Date:  2016-11-02       Impact factor: 4.379

9.  Adherence with single-pill amlodipine/atorvastatin vs a two-pill regimen.

Authors:  Bimal V Patel; R Scott Leslie; Patrick Thiebaud; Michael B Nichol; Simon S K Tang; Henry Solomon; Dennis Honda; JoAnne M Foody
Journal:  Vasc Health Risk Manag       Date:  2008

10.  Efficacy and safety of fixed-dose combination therapy with olmesartan medoxomil and rosuvastatin in Korean patients with mild to moderate hypertension and dyslipidemia: an 8-week, multicenter, randomized, double-blind, factorial-design study (OLSTA-D RCT: OLmesartan rosuvaSTAtin from Daewoong).

Authors:  Jin-Sun Park; Joon-Han Shin; Taek-Jong Hong; Hong-Seog Seo; Wan-Joo Shim; Sang-Hong Baek; Jin-Ok Jeong; Youngkeun Ahn; Woong-Chol Kang; Young-Hak Kim; Sang-Hyun Kim; Min-Su Hyon; Dong-Hoon Choi; Chang-Wook Nam; Tae-Ho Park; Sang-Chol Lee; Hyo-Soo Kim
Journal:  Drug Des Devel Ther       Date:  2016-08-16       Impact factor: 4.162
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.